Elsy is an experienced healthcare operator and strategist.

Elsy began her career at The Boston Consulting Group where she served a
variety of international healthcare clients over ten years as Partner and
Managing Director. Subsequently, Elsy joined Cellectis, an oncology-focused
cell therapy company as Chief Operating Officer. She now leads a healthtech
advisory firm called Bio-Up that she founded in 2019. Elsy serves on the board
of directors of a number of biotech and healthtech companies including
GenSight, NovaDiscovery, and Metafora Biosystems.

Elsy graduated with a degree in engineering from the Ecole Polytechnique as
well as a degree from the Universitat Pompeu Fabra and a degree in
immuno-oncology from the École des Sciences du Cancer - Institut Gustave
Roussy.

Denis is an experienced healthcare operator.

A graduate of ESSEC and INSEAD business schools with a PhD in Pharmacy,
Denis has a deep understanding of the pharmaceutical industry. He has held
important marketing, sales, and strategy positions in France, Europe, and
worldwide and has managed international partnerships within various
pharmaceutical groups (Bayer, Fournier Pharma, ALK). In 2006, he was
appointed General Manager of ALK France. In 2012, he also became Senior
Vice President of the Danish pharmaceutical company specialized in allergy
immunotherapy treatments. Since the end of 2017, he is the Chairman and CEO of
LFB, a biopharmaceutical company specialized in plasma-derived and
recombinant proteins used to treat severe and rare diseases.

Denis lectures at ESSEC business school and was also Chairman of Lecrip.org,
a healthcare think tank.

Jeff is an American physician, researcher, and former Dean of Harvard Medical
School.

Jeffrey S. Flier, M.D., is the Higginson Professor of Physiology and Medicine at
Harvard Medical School (HMS) and Distinguished Service Professor at Harvard
University. He received his M.D. from Mount Sinai School of Medicine in 1972
with the Elster Award for Highest Academic Standing. Following residency
training in internal medicine at Mount Sinai Hospital (1972–1974) and research
training as a Clinical Associate at the National Institutes of Health, Jeff joined
the Faculty of Medicine at HMS and Beth Israel Hospital as Chief of the
Diabetes Unit in 1978. He was later named chief of the hospital’s Endocrine
Division and Vice Chairman of Research. From 2007–2016, Jeff served as the
21st Dean of the Faculty of Medicine at Harvard University. The author of over
200 scholarly papers and reviews, Jeff is one of the leading investigators and
authorities on the molecular causes of obesity and diabetes. His research has
produced major insights into the molecular mechanisms of insulin action and
insulin resistance in human disease, and the molecular pathophysiology of
obesity.

Jeff is an elected member of the Institutes of Medicine and a fellow of the
American Academy of Arts and Sciences. In 2003, he received the Edwin B.
Astwood Lecture Award from the Endocrine Society. The American Diabetes
Association has honored Jeff with the Eli Lilly Award, the Banting Medal in
2005 (the ADA’s highest scientific honor) and the Albert Renold Award for
outstanding achievements in the training of diabetes research scientists and
the facilitation of diabetes research. In 2011, he was awarded the Rolf Luft
Award for Metabolic Research from the Karolinska Institute in Sweden.

Taylor is a healthcare operator with a track record of scaling and leading
high-value, high-growth medtech and biotech companies.

Taylor began his career at JP Morgan as a healthcare investment banker and
equity research analyst focused on the medical device industry. After 12 years
at the firm, Taylor joined the medical device company Thoratec ultimately
serving as CFO. Thoratec marketed mechanical circulatory support products
for the treatment of heart failure patients. Following Thoratec’s acquisition by
St. Jude Medical for approximately $3.4 billion, Taylor joined Zeltiq as CFO.
Zeltiq revolutionized the body contouring, cash-pay medical aesthetics sector
and was subsequently acquired for approximately $2.4 billion by Allergan.
Following that acquisition, Taylor joined the biotech company MyoKardia as
CFO. MyoKardia pioneered a precision medicine approach to treating
cardiomyopathies and other forms of heart failure. Bristol Myers Squibb
acquired MyoKardia in a cash-based transaction valued at $13.1 billion.

Taylor graduated from the University of North Carolina at Chapel Hill as a
Morehead-Cain Scholar with a BA in Physics and Economics.

Stéphane is a professional investor with more than 20 years of experience in
private equity.

Stéphane joined the leading European private equity firm Chequers Capital
early in his career, ultimately becoming Partner and Managing Director.
During his time there, Stéphane was critical to Chequers’ expansion from
solely operating in France to expanding to Germany, Italy, and Spain, all while
driving assets under management to 2.5 Bn€.

Stéphane graduated from the École Polytechnique with a degree in
Engineering and then earned a Master of Science in Petroleum Economics
and Management from IFP.

As a biologist, I was CEO of Biopath-idf between 2011 and 2018, and I accompanied the growth of the medical laboratory from 22 to 78 millions in turnover before joining Unilabs France until December 2020. As a member of the French management committee in charge of sales, marketing and innovation in partnership with the Medical Department and Operations, I participated in many development projects and learned a lot about the medical diagnostics sector (biology, radiology and anatomopathology) in Europe.

Since 2021, I have been managing the PJP Investissements holding company and have been actively involved in the selection and monitoring of investments, both direct and via private equity funds, particularly in the healthcare sector.